CLINICAL TRIALS PROFILE FOR NICODERM CQ

All Clinical Trials for Nicoderm Cq

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00086411 ↗	Comparing Smoking Treatment Programs for Lighter Smokers - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2003-09-01	The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.
NCT00086411 ↗	Comparing Smoking Treatment Programs for Lighter Smokers - 1	Completed	Peter Gariti	Phase 2	2003-09-01	The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.
NCT00086411 ↗	Comparing Smoking Treatment Programs for Lighter Smokers - 1	Completed	University of Pennsylvania	Phase 2	2003-09-01	The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.
NCT00139516 ↗	Chinese Community Smoking Cessation Project	Completed	National Heart, Lung, and Blood Institute (NHLBI)	N/A	2001-09-01	The study has two objectives/aims: Aim 1: To test the efficacy of the intervention among adult smokers with cardiovascular disease, pulmonary disease and diabetes mellitus related illnesses (later modified to Chinese adults with and without diseases); and Aim 2: To examine a set of measures (background, general health, psychosocial, and smoking process) that are associated with smoking cessation at 6 and 12 months
NCT00139516 ↗	Chinese Community Smoking Cessation Project	Completed	University of California, San Francisco	N/A	2001-09-01	The study has two objectives/aims: Aim 1: To test the efficacy of the intervention among adult smokers with cardiovascular disease, pulmonary disease and diabetes mellitus related illnesses (later modified to Chinese adults with and without diseases); and Aim 2: To examine a set of measures (background, general health, psychosocial, and smoking process) that are associated with smoking cessation at 6 and 12 months
NCT00158171 ↗	Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2002-04-01	Currently one in five high school students smokes. Smoking can harm adolescents well before they reach adulthood by causing a number of immediate, sometimes irreversible, health risks and problems. This study will compare the effectiveness of treatment with bupropion, a nicotine patch, or nicotine gum in supporting the reduction of smoking in adolescent smokers.
NCT00218296 ↗	Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use	Completed	University of Minnesota	Phase 2	2006-11-01	Smokeless tobacco (ST), which includes both chewing tobacco and snuff, has health risks associated with its use. While treatment programs that focus on stopping tobacco use may be effective, past research has shown that interventions that specifically focus on reducing tobacco use may be equally effective and may motivate individuals to eventually quit using tobacco. This study will compare the effectiveness of a ST reduction treatment program versus a usual tobacco cessation treatment program (immediate cessation) for reducing tobacco use in ST users.

Clinical Trial Conditions for Nicoderm Cq

Condition Name

Condition Name for Nicoderm Cq
Intervention	Trials
Nicotine Dependence	12
Smoking Cessation	11
Tobacco Use Disorder	7
Smoking	5

Condition MeSH

Condition MeSH for Nicoderm Cq
Intervention	Trials
Tobacco Use Disorder	19
Heart Diseases	2
Cardiovascular Diseases	2
Lung Diseases	1

Clinical Trial Locations for Nicoderm Cq

Trials by Country

Trials by Country for Nicoderm Cq
Location	Trials
United States	30
Canada	8
Uganda	1
Zambia	1

Trials by US State

Trials by US State for Nicoderm Cq
Location	Trials
North Carolina	13
Missouri	3
Wisconsin	2
Minnesota	2
Pennsylvania	2

Clinical Trial Progress for Nicoderm Cq

Clinical Trial Phase

Clinical Trial Phase for Nicoderm Cq
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Nicoderm Cq
Clinical Trial Phase	Trials
Completed	22
Recruiting	5
Enrolling by invitation	3

Clinical Trial Sponsors for Nicoderm Cq

Sponsor Name

Sponsor Name for Nicoderm Cq
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	12
Duke University	9
Centre for Addiction and Mental Health	6

Sponsor Type

Sponsor Type for Nicoderm Cq
Sponsor	Trials
Other	44
NIH	18
Industry	9

Clinical Trials, Market Analysis, and Projections for NicoDerm CQ

Introduction to NicoDerm CQ

NicoDerm CQ is a nicotine replacement therapy (NRT) product designed to help individuals quit smoking. It is available in the form of a transdermal patch, providing sustained nicotine delivery over a 24-hour period.

Clinical Trials and Efficacy

Clinical Trial Outcomes

NicoDerm CQ has been evaluated in several clinical trials to assess its safety and efficacy. Two randomized studies compared the 21 mg/24 hr patch with placebo and with the 15 mg/16 hr patch. These studies demonstrated that NicoDerm CQ was generally well tolerated and effective in aiding smoking cessation[1].

Efficacy in Smoking Cessation

NicoDerm CQ has been shown to double the chances of quitting smoking compared to placebo. The patch utilizes SmartControl Technology, which provides rapid relief and sustained nicotine delivery over 24 hours. This technology enhances the patch's efficacy in managing nicotine cravings and withdrawal symptoms[5].

Market Analysis

Current Market Share

In the over-the-counter (OTC) nicotine replacement therapy market, NicoDerm CQ holds a significant share, although it is smaller compared to other leading brands. As of recent data, NicoDerm CQ accounts for about 5.7% of the OTC NRT market, with the majority being dominated by private label and Nicorette products[3].

Sales Trends

The sales of OTC NRT products, including NicoDerm CQ patches, have shown varying trends. Between 2017 and 2020, the total quarterly sales of OTC NRT significantly decreased, with gum and patches experiencing a decline, while lozenges saw an initial increase followed by a significant drop starting in 2020[3].

Market Projections

Global Transdermal Patch Market

The global transdermal patch market, which includes NicoDerm CQ, is projected to grow substantially. By 2026, the global transdermal patch market is expected to surpass $15 billion, driven by the advantages of painless and non-invasive administration, ease of use, and prolonged drug activation[4].

Specific Projections for NicoDerm CQ

While specific projections for NicoDerm CQ are not isolated from the broader transdermal patch market, the growing demand for NRT products and the unique features of NicoDerm CQ, such as its SmartControl Technology, suggest continued market relevance. The overall trend in the NRT market indicates a shift towards more convenient and effective products, which could favor NicoDerm CQ.

Regional Market Insights

Global NRT Market

The global NRT market, including nicotine patches, is influenced by regional preferences and regulatory environments. For instance, the nicotine pouches market, another segment of NRT, is growing rapidly in Scandinavia and the UK, driven by consumer preference for tobacco-free products and regulatory changes[2].

Regional Growth for Transdermal Patches

The transdermal patch market, including NicoDerm CQ, is expected to see significant growth in various regions. The Asia-Pacific region, in particular, is anticipated to experience rapid growth due to urbanization, increasing per capita income, and attractive marketing strategies by global players[2].

Consumer Preferences and Trends

Flavor Preferences

Consumer preferences play a crucial role in the NRT market. Mint flavor remains the most popular across NRT products, including gum and lozenges, which could influence the demand for NicoDerm CQ patches as well[3].

Alternative NRT Products

The rise of alternative NRT products, such as nicotine pouches, is also impacting the market. Nicotine pouches, which do not involve lung exposure, are gaining popularity, especially among younger consumers. This trend could influence the overall NRT market, including the demand for transdermal patches like NicoDerm CQ[2].

Key Takeaways

• Clinical Efficacy: NicoDerm CQ has been proven to double the chances of quitting smoking compared to placebo.
• Market Share: NicoDerm CQ holds a significant but smaller share in the OTC NRT market.
• Sales Trends: The sales of OTC NRT products, including NicoDerm CQ patches, have shown declining trends in recent years.
• Market Projections: The global transdermal patch market is expected to grow substantially, surpassing $15 billion by 2026.
• Regional Insights: The market is influenced by regional preferences and regulatory environments, with significant growth expected in the Asia-Pacific region.

FAQs

What is NicoDerm CQ?

NicoDerm CQ is a nicotine replacement therapy (NRT) product available in the form of a transdermal patch, designed to help individuals quit smoking.

How effective is NicoDerm CQ in quitting smoking?

NicoDerm CQ has been shown to double the chances of quitting smoking compared to placebo, providing sustained nicotine delivery over 24 hours.

What is the current market share of NicoDerm CQ in the OTC NRT market?

NicoDerm CQ accounts for about 5.7% of the OTC NRT market, with the majority being dominated by private label and Nicorette products.

What are the projected growth trends for the transdermal patch market?

The global transdermal patch market is expected to surpass $15 billion by 2026, driven by the advantages of painless and non-invasive administration.

How do regional preferences influence the demand for NicoDerm CQ?

Regional preferences and regulatory environments significantly influence the demand for NRT products. For example, the Asia-Pacific region is expected to experience rapid growth due to urbanization and increasing per capita income.

What are the consumer preferences in the NRT market?

Mint flavor remains the most popular across NRT products, and there is a growing preference for alternative products like nicotine pouches that do not involve lung exposure.

Sources

1. NicoDerm CQ Patch Safety Information - Haleon HealthPartners
2. Nicotine Pouches Market Size & Share | Industry Report 2030 - Grand View Research
3. Trends in Over-the-Counter Nicotine Replacement Therapy Sales - CDC Stacks
4. Transdermal Patch Market Study 2020-2026 - Markets Business Insider
5. NicoDerm CQ Clear Patch Efficacy - Haleon Health Partner